c-MYC, RB-1, TP53, and centromere 8 and 17 copy number in B-cell Non- Hodgkin's lymphomas assessed by dual-color fluorescence in situ hybridization

Communications in Clinical Cytometry

Volumn 38, Issue 2, 1999, Pages 53-60

  Galteland, Eivind ^a   Holte, Harald ^a   Stokke, Trond ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

B cell NHL; c MYC; FISH; RB 1; TP53

Indexed keywords

ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CENTROMERE; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HISTOLOGY; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; ONCOGENE C MYC; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

CENTROMERE; CHROMOSOME ABERRATIONS; FEMALE; GENE DOSAGE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MYC; RETINOBLASTOMA PROTEIN; SURVIVORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033560838     PISSN: 01964763     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0320(19990415)38:2<53::AID-CYTO2>3.0.CO;2-0     Document Type: Article

References (39)

1. Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma. Blood 1986;68:1-31.
2. Pinkel D, Sakamoto M, Matsumura K, Kallioniemi A, Kallioniemi OP, Waldman F, Gray J. Application of fluorescence in situ hybridization to detection of chromosomal aberrations. Cytometry Res 1992;2:1-11.
3. Depinho R, Schreiber-Agus N, Alt FW. Myc family oncogenes in the development of normal and neoplastic cells. Cancer Res 1991;57:1-46.
4. Amati B, Land H. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev 1994;4:102-108.
5. Evan G, Wyllie A, Gilbert C, Littlewood T, Land H, Brooks M, Waters C, Penn L, Hancock D. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-128.
6. Dalla-Favera R, Bregni M, Ericson J, Patterson D, Gallo RC, Croce CM. Human c-myc oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982;79:7824-7826.
7. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-456.
8. Goodrich DW, Wang NP, Quian YW, Lee EYHP, Lee WH. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991;67:293-302.
9. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-347.
10. Ishii H, Igarashi T, Saito T, Nakano T, Mori M, Ohyama H, Miyamoto T, Saito Y, Oh H. Retinoblastoma protein expressed in human non-Hodgkin's lymphoma cells generates resistance against radiation-induced apoptosis. Am J Hematol 1997;55:46-48.
11. Haas-Kogan DA, Kogan SC, Levi D, Dazin P, T'Ang A, Fung YK, Israel MA. Inhibition of apoptosis by the retinoblastoma gene product EMBO J 1995;14:461-472.
12. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM, Dryja TP. A human DNS segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986;323: 643.
13. Hangaishi A, Ogawa S, Imamura N, Miyawaki S, Miura Y, Uike N, Shimazaki C, Emi N, Takeyama K, Hirosawa S, et al. Inactivation of multiple tumor-suppressor genes involved in negative regulation of the cell cycle, MTS1/p16INK4A/CDKN2, MTS2/p15INK4B, p53, and RB genes in primary lymphoid malignancies. Blood 1996;87:4949-4958.
14. Weide R, Tiemann M, Pflüger KH, Köppler H, Parvizl B, Wacker HH, Kreipe HH, Havemann K, Parwaresch MR. Altered expression of the retinoblastoma gene product in human high grade non-Hodgkin's lymphomas. Leukemia 1994;8:97-101.
15. Martinez JC, Piris MA, Sanchez-Beato M, Villuendas R, Orradre JL, Algara P, Sanchez-Verde L, Martinez P. Retinoblastoma (Rb) gene product expression in lymphomas. Correlation with Ki67 growth fraction. J Pathol 1993;169:405.
16. Döhner H, Pilz T, Fischer K, Cabot G, Diehl D, Fink T, Stilgenbauer S, Bentz M, Lichter P. Molecular cytogenetics analysis of RB-1 deletions in chronic B-cell leukemias. Leuk Lymphoma 1994;16:97-103.
17. Martinez-Delgado B, Robledo M, Arranz E, Infantes F, Echezarreta G, Marcos B, Sanz C, Rivas C, Benitez J. Correlation between mutations in p53 gene and protein expression in human lymphomas. Am J Hematol 1997;55:1-8.
18. Adamson DJA, Thompson WD, Dawson AA, Bennet B, Haites NE. p53 mutation and expression in lymphoma. Br J Cancer 1995;72:150-154, 1995.
19. Villuendas R, Piris MA, Algara P, Sanchez-Beato M, Sanchez-Verde L, Martinz JC, Orradre JL, Garcia P, Lopez C, Martinez P. The expression of p53 protein in non-Hodgkin's lymphomas is not always dependent on p53 gene mutations. Blood 1993;82:3151-3156.
20. Doglioni C, Pelosio P, Mombello A, Scarpa A, Chilosi M. Immunohistochemical evidence of abnormal expression of the antioncogene-encoded p53 phosphoprotein in Hodgkin's disease and CD30+ anaplastic lymphomas. Hematol-Pathol 1991;5:67-73.
21. Louie DC, Offit K, Jaslow R, Parsa NZ, Murty VV, Schluger A, Chaganti RS. p53 expression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood 1995;86:2892-2899.
22. Newcomb EW. P53 gene mutations in lymphoid diseases and their possible relevance to drug resistance. Leuk Lymphoma 1995;17:211-221.
23. Rodriquez MA, Ford RJ, Goodacre A, Selvanayagam P, Cabanillas F, Deisseroth B. Chromosome 17p and p53 changes in lymphoma. Br J Hematol 1991;79:575-582.
24. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S. p53 gene deletions predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995;85:1580-1589.
25. Clodi K, Younes A, Goodacre A, Roberts M, Palmer J, Younes M, Cabanillas F, Andreeff M. Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization. Br J Haematol 1997;98:913-921.
26. Kvaløy S, Godal T, Marton PF, Steen HB, Brennhovd IO, Foss-Abrahamsen A. Spontaneous 3H-thymidine uptake in histological subgroups of human B-cell lymphomas. Scand J Haematol 1981;26:221-234.
27. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, Sundstrøm C, Lennert K, Unnik JAM, Mioduszewska O, Wright DH. Updated Kiel classification for lymphomas. Lancet 1998;1:292-293.
28. Stokke T, Holte H, Smedshammer L, Smeland EB, Kaalhus O, Steen HB. Proliferation and apoptosis in malignant and normal cells in B-cell Non-Hodgkin's lymphomas. Br J Cancer 1998;77:1832-1838.
29. Visscher DW, Wallis T, Awussah S, Mohamed A, Crissman JD. Evaluation of myc and chromosome 8 copy number in breast carcinoma by interphase cytogenetics. Genes Chromosomes Cancer 1997;18:1-7.
30. Sauter G, Carroll P, Moch H, Kallioniemi A, Kerschmann R, Narayan P, Mihatsch MJ, Waldman FM. c-myc copy number gains in bladder cancer detected by fluorescence in situ hybridization. Am J Pathol 1995;146:1131-1139.
31. Stilgenbauer S, Leupolt E, Ohl S, Weiss G, Schroder M, Fischer K, Bentz M, Lichter P, Dohner H. Heterogeneity of deletions involving RB-1 and the D13S25 locus in B-cell chronic lymphocytic leukemia revealed by fluorescence in situ hybridization. Cancer Res 1995;55: 3475-3477.
32. Piris MA, Villuendas R, Martinez JC, Sanchez-Beato M, Orradre JL, Mateo MS, Martinez P. p53 expression in non-Hodgkin's lymphomas: a marker of p53 inactivation? Leuk Lymphoma 1995;17:35-42.
33. Maestro R, Gloghini A, Doglioni C, Gasparotto D, Vukosavljevic T, De-Re V, Laurino L, Carbone A, Boiocchi M. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood 1995;85:3239-3246.
34. Jendiroba D, Younes A, Katz R, Hill D, Cabanillas F, Andreeff M. Chromosome 17 numerical abnormalities in 55 patients with non-Hodgkin's lymphoma: a fluorescence in situ hybridization study. Leukemia 1995;9:1144-1146.
35. Kuukasjärvi T, Karhu R, Tanner M, Kähkönen M, Schäffer A, Nupponen N, Pennanen S, Kallioniemi A, Kallioniemi OP, Isola J. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 1997;57: 1597-1604.
36. Simpson JF, Quan DE, Ho JP, Slovak ML. Genetic heterogeneity of primary and metastatic breast carcinoma defined by fluorescence in situ hybridization. Am J Pathol 1996;149:751-758.
37. Augenlicht LH, Wadler S, Corner G, Richards C, Ryan L, Multani AS, Pathak S, Benson A, Haller D, Heerdt BG. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 1997;57:1769-1775.
38. Heerdt BG, Molinas S, Deitch D, Augenlicht LH. Agressive subtypes of human colorectal tumors frequently exhibit amplification of the c-myc gene. Oncogene 1991;6:125-129.
39. Stokke T, Smeland EB, Kvaløy S, Holte H. Tumour cell proliferation, but not apoptosis, predicts survival in B-cell non-Hodgkin's lymphomas. Br J Cancer 1998;77:1839-1845.